AVROXA
0687.774.936 · rovalta.com · 20/09/2026
AVROXA
Overview
What does AVROXA do?
AVROXA is a Private limited company incorporated in 2018. Its registered office is in Gent. It employs on average 1,0 ETP workers (FTE).
9052 Gent · FlandreSee on map
Joint committees (2)
- 2070
- 207000
Trend over 7 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Gross margin | 170,8 k € | -84.9% | 1,1 M € | +12.2% | 1,0 M € | +185% | 354,7 k € | +7.6% | 329,5 k € | -2.2% | 336,9 k € | +970% | 31,5 k € |
| EBITDA | 95,9 k € | -91.0% | 1,1 M € | +17.9% | 901,2 k € | +391% | 183,4 k € | +24.8% | 146,9 k € | -45.9% | 271,4 k € | +784% | 30,7 k € |
| Operating result | -36,1 k € | -104% | 961,9 k € | +41.2% | 681,2 k € | +1631% | -44,5 k € | -39.6% | -31,9 k € | -117% | 190,4 k € | +520% | 30,7 k € |
| Net result | -32,5 k € | -104% | 815,0 k € | +41.4% | 576,6 k € | +1363% | -45,7 k € | -33.3% | -34,3 k € | -118% | 190,2 k € | +679% | 24,4 k € |
| Balance sheet | |||||||||||||
| Equity | 869,0 k € | -44.9% | 1,6 M € | +107% | 760,8 k € | +183% | 268,8 k € | -38.6% | 437,9 k € | -19.0% | 540,5 k € | +1453% | 34,8 k € |
| Total assets | 1,8 M € | -6.4% | 1,9 M € | +89.2% | 1,0 M € | +128% | 445,5 k € | -31.8% | 653,4 k € | -12.7% | 748,1 k € | +281% | 196,4 k € |
| Cash | 1,5 M € | +14.7% | 1,3 M € | +95.2% | 671,9 k € | +296% | 169,7 k € | -32.2% | 250,1 k € | -27.5% | 344,7 k € | +167% | 129,2 k € |
| Debts | 903,2 k € | +204% | 296,9 k € | +88.5% | 157,5 k € | +50.7% | 104,5 k € | -22.3% | 134,5 k € | +129% | 58,6 k € | +49.7% | 39,2 k € |
| Other | |||||||||||||
| Workforce | 1,0 ETP | 0.0% | 1,0 ETP | – | – | – | – | – | |||||
Indicative valuation
As an indication, this company is worth
Board of directors
Seen on filing of 31/12/2025 · 2 active · 8 ended
Active mandates
Ended mandates
Other companies at this address
| Company | CBE no. |
|---|---|
Amalus Therapeutics● Bankrupt | 0803.929.268 |
APCOR R&M● Active | 0600.952.909 |
Ardoyen● Active | 0875.102.821 |
Benebiose● Active | 0784.521.548 |
BioNeering● Active | 0807.194.309 |
CONTREL EUROPE● Active | 0426.204.637 |
CRODEON TECHNOLOGIES● Active | 0642.754.761 |
Cryptobiotix● Active | 0762.565.104 |
Gulliver Biomed● Active | 0692.527.837 |
ImplicitMeasures.com● Bankrupt | 0657.989.701 |
Inbiose● Active | 0534.887.593 |
| 0440.054.752 | |
INNOVATIVE PHARMACEUTICS● Active | 0883.574.582 |
Inspect● Active | 0645.950.417 |
INVIBES ADVERTISING● Active | 0836.533.938 |
KYTOS● Active | 0768.755.286 |
Lares Solutions● Active | 1015.346.906 |
| 0755.350.975 | |
| 0742.910.132 | |
| 0667.765.816 |
Financials
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 16/07/2026 | 23/12/2025 | 01/10/2024 | 30/08/2023 | 24/08/2022 | 13/08/2021 |
| General meeting | 20/06/2026 | 31/10/2025 | 31/08/2024 | 29/08/2023 | 30/07/2022 | 31/07/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Looking for more information about this company?
Try for 7 daysAnnual accounts filings
8 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 20/06/2026 | 16/07/2026 | Dutch | |
| Abridged model | 31/12/2024 | 31/10/2025 | 23/12/2025 | Dutch | |
| Micro model | 31/12/2023 | 31/08/2024 | 01/10/2024 | Dutch | |
| Micro model | 31/12/2022 | 29/08/2023 | 30/08/2023 | Dutch | |
| Micro model | 31/12/2021 | 30/07/2022 | 24/08/2022 | Dutch | |
| Micro model | 31/12/2020 | 31/07/2021 | 13/08/2021 | Dutch | |
| Micro model | 31/12/2019 | 20/06/2020 | 13/07/2020 | Dutch | |
| Micro model | 31/12/2018 | 15/06/2019 | 10/07/2019 | Dutch |
Valuation
Indicative valuation
As an indication, this company is worth
between 2,5 M€ and 5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Seen on filing of 31/12/2025 · 2 active · 8 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
- Mandates30/01/2024STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM - ONTSLAGEN - BENOEMINGEN
- Mandates18/05/2021ONTSLAGEN - BENOEMINGEN - WIJZIGING RECHTSVORM
- Registered office25/01/2019MAATSCHAPPELIJKE ZETEL
- Other12/01/2018RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
Source: Belgian Official Gazette
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-32,5 k €↓
- 2024Annual accounts 2024815,0 k €↑
- 2023Annual accounts 2023576,6 k €↑
- 2022Annual accounts 2022-45,7 k €↓
- 2021Annual accounts 2021-34,3 k €↓
- 2019Annual accounts 2019190,2 k €↑
- 2018Annual accounts 201824,4 k €
- 10/01/2018IncorporationPrivate limited company